ASCENDIS PHARMA A/S - ADR (ASND) Stock Price & Overview
NASDAQ:ASND • US04351P1012
Current stock price
The current stock price of ASND is 249.84 USD. Today ASND is up by 0.52%. In the past month the price increased by 8.14%. In the past year, price increased by 51.37%.
ASND Key Statistics
- Market Cap
- 15.114B
- P/E
- N/A
- Fwd P/E
- 47.65
- EPS (TTM)
- -4.45
- Dividend Yield
- N/A
ASND Stock Performance
ASND Stock Chart
ASND Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ASND. When comparing the yearly performance of all stocks, ASND is one of the better performing stocks in the market, outperforming 85.34% of all stocks.
ASND Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ASND. Both the profitability and financial health of ASND have multiple concerns.
ASND Earnings
On February 11, 2026 ASND reported an EPS of -0.55 and a revenue of 247.50M. The company missed EPS expectations (-1098.26% surprise) and missed revenue expectations (-1.48% surprise).
ASND Forecast & Estimates
24 analysts have analysed ASND and the average price target is 299.54 USD. This implies a price increase of 19.89% is expected in the next year compared to the current price of 249.84.
For the next year, analysts expect an EPS growth of 217.92% and a revenue growth 95.11% for ASND
ASND Groups
Sector & Classification
ASND Financial Highlights
Over the last trailing twelve months ASND reported a non-GAAP Earnings per Share(EPS) of -4.45. The EPS increased by 42.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.51% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ASND Ownership
ASND Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.18 | 371.899B | ||
| AMGN | AMGEN INC | 15.37 | 189.187B | ||
| GILD | GILEAD SCIENCES INC | 15.89 | 174.329B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 113.007B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.12 | 79.873B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.72 | 45.013B | ||
| INSM | INSMED INC | N/A | 33.111B | ||
| NTRA | NATERA INC | N/A | 30.421B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.133B | ||
| BIIB | BIOGEN INC | 11.1 | 26.264B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.79 | 25.357B | ||
| MRNA | MODERNA INC | N/A | 20.956B | ||
| INCY | INCYTE CORP | 12.62 | 19.441B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ASND
Company Profile
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Company Info
IPO: 2015-01-28
ASCENDIS PHARMA A/S - ADR
Tuborg Boulevard 12
Hellerup 2900 DK
CEO: Jan Moller Mikkelsen
Employees: 1189
Phone: 4570222244
ASCENDIS PHARMA A/S - ADR / ASND FAQ
Can you describe the business of ASCENDIS PHARMA A/S - ADR?
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Can you provide the latest stock price for ASCENDIS PHARMA A/S - ADR?
The current stock price of ASND is 249.84 USD. The price increased by 0.52% in the last trading session.
Does ASCENDIS PHARMA A/S - ADR pay dividends?
ASND does not pay a dividend.
What is the ChartMill rating of ASCENDIS PHARMA A/S - ADR stock?
ASND has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is ASCENDIS PHARMA A/S - ADR (ASND) stock traded?
ASND stock is listed on the Nasdaq exchange.
Can you provide the upcoming earnings date for ASCENDIS PHARMA A/S - ADR?
ASCENDIS PHARMA A/S - ADR (ASND) will report earnings on 2026-04-29, after the market close.